A study reported that glioblastoma patients often exhibit a hypercoagulable profile, characterized by reduced prothrombin time (PT) and activated partial thromboplastin time (aPTT), along with elevated levels of D-dimer and von Willebrand factor (VWF), all of which are associated with adverse survival outcomes [14]. This evidence concerns the gene F2 and glioblastoma.